Abstract：Objective To study therapy efficacy of small dose peg-interferon plus ribavirin on recurrent Hepatitis C patients of post liver transplantation. Methods The patients were accepted the therapy of Pegasys 90ug/week, after two weeks 135 ug/week,Ribavirin 600mg/day, who were recurrence with Hepatitis C post liver transplantation from June, 2002 to April, 2012 in our hospital. The titer of HCV-RNA, liver function, blood routine and clinical presents were monitoring at 6th week, 12 th week and 24th week during the therapy. Results There were 22 cases were accepted the therapy of small dose peg-interferon plus ribavirin. The rate of early virological response(EVR) was 90.9%. The rate of end-of-treatment virological response(ETVR) was 100.0%. The sustained virological response (SVR) was 81.8%. There was significant increase of the activity of cholinesterase after 24 weeks treatment (P=0.013). The mild abnormality was taken place in the blood routine, hemoglobin 54.5%, platelet 68.2% and leucocyte 27.3%. Severe fever, skin lesion and alopecia were not taken place in these cases. Conclusions The rates of EVR, ETVR and SVR are high, and the liver synthetic ability of patients are elevated without serious side-effect after treated small dose peg-interferon plus ribavirin.
范铁艳,陈虹,沈中阳,田彦,杨洋. 小剂量长效干扰素联合利巴韦林治疗肝移植术后丙肝复发[J]. 武警医学, 2013, 24(6): 507-510.
FAN Tieyan,CHEN Hong,SHEN Zhongyang,TIAN Yan,and YANG Yang. The therapy efficacy of small dose peg-interferon plus ribavirin on recurrent Hepatitis C patients of post liver transplantation. Med. J. Chin. Peop. Armed Poli. Forc., 2013, 24(6): 507-510.
Wiesner R H, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C [J]. Liver Transpl, 2003, 9(11): S1-S9.
[1]
Wiesner R H, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C [J]. Liver Transpl, 2003, 9(11): S1-S9.
[2]
Yilmaz N, Shiffman M L, Stravitz RT,et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation [J]. Liver Transpl, 2007, 13(7):975-983.
[2]
Yilmaz N, Shiffman M L, Stravitz RT,et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation [J]. Liver Transpl, 2007, 13(7):975-983.
[3]
Thuluvath P J, Krok K L, Segev D L, et al. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States [J]. Liver Transpl, 2007, 13(5):719-724.
[3]
Thuluvath P J, Krok K L, Segev D L, et al. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States [J]. Liver Transpl, 2007, 13(5):719-724.
[4]
Forman L M, Lewis J D, Berlin J A, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation [J]. Gastroenterology, 2002, 122(4):889-896.
[4]
Forman L M, Lewis J D, Berlin J A, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation [J]. Gastroenterology, 2002, 122(4):889-896.
[5]
Hanouneh I A, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy [J]. Liver Transpl, 2008, 14(1):53-58.
[5]
Hanouneh I A, Miller C, Aucejo F, et al. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy [J]. Liver Transpl, 2008, 14(1):53-58.
[6]
Ueda Y, Takada Y, Marusawa H, et al. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation [J]. Transplantation, 2010, 90(6):661-665.
[7]
Ueda Y, Kaido T, Ogura Y, et al. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation[J]. 2013,8(3):e58380. doi: 10.1371.
[6]
Ueda Y, Takada Y, Marusawa H, et al. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation [J]. Transplantation, 2010, 90(6):661-665.
[7]
Ueda Y, Kaido T, Ogura Y, et al. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation[J]. 2013,8(3):e58380. doi: 10.1371.
[8]
Ponziani F R, Milani A, Gasbarrini A, et al. Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response[J]. An AISF RECOLT-C group study Ann Hepatol, 2012,11(3):338-342.
[8]
Ponziani F R, Milani A, Gasbarrini A, et al. Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response[J]. An AISF RECOLT-C group study Ann Hepatol, 2012,11(3):338-342.
[9]
Terrault N. Liver transplantation in the setting of chronic HCV[J].Best Pract Res Clin Gastroenterol, 2012,26(4):531-548.
[9]
Terrault N. Liver transplantation in the setting of chronic HCV[J].Best Pract Res Clin Gastroenterol, 2012,26(4):531-548.
[10]
García-Pajares F, Almohalla C, Lorenzo Pelayo S,et al. Early and extended therapy for recurrent hepatitis C after liver transplantation [J]. Transplant Proc, 2012, 44(6):1571-1573.
[10]
García-Pajares F, Almohalla C, Lorenzo Pelayo S,et al. Early and extended therapy for recurrent hepatitis C after liver transplantation [J]. Transplant Proc, 2012, 44(6):1571-1573.
[11]
Bereguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin [J]. J Hepatol, 2008, 49(2):274-287.
[12]
Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C [J]. Liver Transpl, 2006,12(7):1067-1076.
[11]
Bereguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin [J]. J Hepatol, 2008, 49(2):274-287.
[12]
Berenguer M, Palau A, Fernandez A, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C [J]. Liver Transpl, 2006,12(7):1067-1076.
[13]
Koretz R L, Pleguezuelo M, Arvaniti V, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C[J]. Cochrane Database Syst Rev, 2013,31:1.
[14]
Oton E, Barcena R, Moreno-Planas J M, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin [J]. AM J Tansplant, 2006, 6(10): 2348-2355.
[13]
Koretz R L, Pleguezuelo M, Arvaniti V, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C[J]. Cochrane Database Syst Rev, 2013,31:1.
[15]
Lodato F, Berardi S, Gramenzi A, et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation [J]. Aliment Pharmacol Ther, 2008, 28(4):450-457.
[14]
Oton E, Barcena R, Moreno-Planas J M, et al. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin [J]. AM J Tansplant, 2006, 6(10): 2348-2355.
[16]
Sharma P, Marrero J A, Fontana R J, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence [J]. Liver Transpl, 2007, 13(8):1100-1108.
[15]
Lodato F, Berardi S, Gramenzi A, et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation [J]. Aliment Pharmacol Ther, 2008, 28(4):450-457.
[16]
Sharma P, Marrero J A, Fontana R J, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence [J]. Liver Transpl, 2007, 13(8):1100-1108.
[17]
Iwasa M, Hara N, Miyachi H, et al. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels[J]. J Viral Hepat, 2009, 16(10):716-723.
[17]
Iwasa M, Hara N, Miyachi H, et al. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels[J]. J Viral Hepat, 2009, 16(10):716-723.
[18]
Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients[J]. Transplantation, 2010, 90(11):1204-1209.
[19]
Shima T, Tada H, Morimoto M, et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment [J]. J Gastroenterol Hepatol, 2000, 15(3):294-299.
[18]
Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients[J]. Transplantation, 2010, 90(11):1204-1209.
[20]
Calmus Y, Duvoux C, Pageaux G, et al. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin [J]. J Hepatol, 2012, 57(3):564-571.
[19]
Shima T, Tada H, Morimoto M, et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment [J]. J Gastroenterol Hepatol, 2000, 15(3):294-299.
[21]
García-Pajares F, Almohalla C, Lorenzo Pelayo S, et al. Early and extended therapy for recurrent hepatitis C after liver transplantation[J]. Transplant Proc, 2012,44(6):1571-1573.
[20]
Calmus Y, Duvoux C, Pageaux G, et al. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin [J]. J Hepatol, 2012, 57(3):564-571.
[21]
García-Pajares F, Almohalla C, Lorenzo Pelayo S, et al. Early and extended therapy for recurrent hepatitis C after liver transplantation[J]. Transplant Proc, 2012,44(6):1571-1573.
[22]
Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients [J]. Liver Transpl, 2004, 10(7):859-867.
[22]
Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients [J]. Liver Transpl, 2004, 10(7):859-867.
[23]
Alghamdi A S, Sanai F M, Ismail M, et al. SASLT practice guidelines: management of hepatitis C virus infection [J]. Saudi J Gastroenterol, 2012, 18(Suppl):S1-32.
[23]
Alghamdi A S, Sanai F M, Ismail M, et al. SASLT practice guidelines: management of hepatitis C virus infection [J]. Saudi J Gastroenterol, 2012, 18(Suppl):S1-32.
2013, Vol. 24 
